Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Neurol India ; 71(4): 737-741, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37635507

RESUMO

Background: There is an agreement among individuals from different cultures in how they judge the cuteness of a face. There are observations suggesting that some preferences may be neurobiological rather than cultural. Most of the studies conducted use adult faces with a neutral expression; however, the mechanisms involved in rating cuteness are not exactly the same as those involved in the perception of attractiveness. Furthermore, it is not always taken into account that emotional expressions influence the impression on the beauty of a face. The objective of the study is to evaluate the influence of the different emotions on the perception of cuteness of children's faces. Materials and Methods: We included 60 adults and 21 children who observed 150 photographs of children's faces expressing the six basic emotions and had to rate facial cuteness. Results: Participants gave the highest cuteness score to faces with happy emotions (mean [M] = 6.89, 95% confidence interval [CI] 6.48-7.30) and the lowest to those that expressed negative emotions (M = 5.32, 95% CI 4.87-5.78, t(160) = 5.08, P <.001). This was evidenced in adults and children of both genders, regardless of the gender of the stimulus. Conclusions: In our study, we found that facial expression generates an impact on the perception that a subject has on the cuteness of the face. The faces that show happiness were scored as more cute compared to those that expressed anger, disgust, or sadness. We suggest that expression of positive emotions, like a smile, could increase the conducts associated with caring, placing the child in a more favorable situation for the future.


Assuntos
Emoções , Felicidade , Adulto , Criança , Humanos , Masculino , Feminino , Expressão Facial , Estimulação Luminosa
2.
Neurol India ; 69(1): 102-106, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33642279

RESUMO

INTRODUCTION: Verbal fluency test is a short psychometric test, which is sensitive to verbal ability and executive control impairment. We did not find studies that analyze verbal fluency in relation to the neurodevelopmental disorders in Spanish-speaking children with letters P-M. Our objective was to analyze the verbal fluency of Spanish-speaking children with neurodevelopmental disorders. METHOD: We carried out a retrospective cross-sectional study to analyze the performance of children who had undergone a neuropsychological assessment. RESULTS: We included 164 patients. There were 55 (33.54%) patients with low intellectual performance (LIP), 19 (11.59%) patients with dyslexia , and 90 (54.88%) patients had an ADHD. Patients with LIP showed lower phonological fluency than patients with ADHD. As for semantic fluidity, differences were observed between patients with LIP and ADHD and also between LIP and dyslexia. The probability of having LIP was 9.6 times greater when somebody had a scale score lower than 7 in the PF task and it was 16.7 times greater when the scale score was lower than 7 in the SF task. CONCLUSIONS: There was a direct relationship between FSIQ and the performance in verbal fluency test, which is a brief and effective neuropsychological test in revealing deficits in executive functions, verbal abilities, and LIP.


Assuntos
Transtornos do Neurodesenvolvimento , Comportamento Verbal , Criança , Estudos Transversais , Humanos , Linguística , Transtornos do Neurodesenvolvimento/diagnóstico , Testes Neuropsicológicos , Estudos Retrospectivos
3.
Acta neurol. colomb ; 33(3): 142-147, jul.-set. 2017. tab, graf
Artigo em Espanhol | LILACS | ID: biblio-886438

RESUMO

RESUMEN INTRODUCCIÓN: La fluencia verbal es un test psicométrico breve utilizado en evaluaciones neuropsicológicas para estudiar funciones ejecutivas y verbales. El desempeño en la población pediátrica en esta prueba no ha sido profundamente estudiado. Tampoco encontramos estudios en pediatría que analicen la fluidez verbal fonológica (FF) en relación al nivel intelectual utilizando la versión española con letras iniciales "P" y "M". OBJETIVO: Analizar el rendimiento en FF en función del nivel intelectual y del diagnóstico. MÉTODO: Corte transversal. Se incluyeron pacientes entre 6 y 16 años con evaluación neuropsicológica con nivel intelectual (WISCIV) y FF (NEPSYII) entre enero y junio del 2016. Se realizó una regresión lineal simple para analizar la relación entre FF y el resto de las variables de estudio. RESULTADOS: Se incluyeron 95 pacientes, edad media de 10 años. La FF mostró correlación positiva con el nivel intelectual total (CIT) (r=3,71; p<0,001; IC95 % 2,77- 4,65). El 73 % de pacientes con FF normal tuvieron un CIT normal. La probabilidad de presentar un CIT descendido presentado una FF menor de 7 fue 5,5 veces mayor (OR=5,5 p<0,003; IC95 %=2,23-13,76). Quienes presentaron una FF descendida con CIT normal (n=19), El 80 % tenía diagnóstico de trastorno por déficit de atención (15/19) y 21 % dislexia (4/19). CONCLUSIONES: Nuestros resultados tienen una importante implicancia clínica, pues no siempre se dispone del acceso y tiempo necesario para realizar una evaluación neuropsicológica extensa. El presente trabajo demuestra que la prueba FF de rápida administración con letras "P" y "M" resulta una herramienta de screening neuropsicológica efectiva en revelar déficit no sólo en funciones ejecutivas y habilidades verbales, sino también en detectar el rendimiento intelectual descendido.


SUMMARY INTRODUCTION: Verbal fluency is a brief psychometric test used in neuropsychological assessments to study executive and verbal functions. Pediatric population performance in this trial has not been thoroughly studied. We also did not find studies in pediatrics that analyze the phonological verbal fluency (FF) in relation to the intellectual level using the Spanish version with initial letters "P" and "M". OBJECTIVE: Analyze FF performance based on intellectual level and diagnosis. METHODS: It's a cross-section research. We included patients between 6 and 16 years old with neuropsychological assessment with intellectual level (WISCIV) and FF (NEPSYII) between January and June of 2016. A simple linear regression was performed to analyze the relationship between FF and the rest of the variables. RESULTS: We included 95 patients, mean age of 10 years. The FF showed a positive correlation with the total intellectual level (ITC) (r = 3.71, p <0.001, 95% CI 2.77-4.65). The 73% of patients with normal FF had a normal ITC. The probability of showing a lower ITC when the FF was lower than 7 was 5.5 times greater (OR = 5.5, p <0.003, 95% CI = 2.23-13.76). Those who presented a lower FF with normal ITC (n = 19) 80% had diagnosis of Attention Deficit Disorder (15/19) and 21% dyslexia (4/19). CONCLUSIONS: Our results have important clinical implications because the access and time necessary for an extensive neuropsychological evaluation is not always available. The present research shows that FF of 2 minutes long with letters "P" and "M" is an effective neuropsychological screening tool in revealing deficit not only in executive functions and verbal abilities, but also in detecting decreased intellectual performance. Those patients with poor performance in this test should perform a complete neuropsychological assesment in order to clarify the diagnosis.


Assuntos
Transtorno do Deficit de Atenção com Hiperatividade , Distúrbios da Fala , Dislexia , Inteligência , Deficiência Intelectual , Testes Neuropsicológicos
4.
Vertex ; 25(114): 85-91, 2014.
Artigo em Espanhol | MEDLINE | ID: mdl-25153973

RESUMO

The aim of the study was to analyze the impact of treatment with vitamin D in the progression of Alzheimer's disease. We performed a retrospective study including patients with mild stage of Alzheimer's disease with more than four years of follow-up. The presence of cardiovascular risk factors, osteoporosis, treatment with memantine, acetylcholinesterase inhibitors drugs and vitamin D were analyzed as independent variables. Time of progression to moderate and severe Alzheimer's disease was analyzed as dependent variable. The analysis was done using multivariate linear regression model, Kaplan Meier analysis, Chi-square and T test. Two hundred and two patients met the inclusion criteria. 11% of the patients (n = 23) remained in the mild stage of the disease, 54% (n = 110) developed the moderate form in a mean time of 3 ± 1.4 years while 35% (n = 69) developed the severe form in a mean time of 4.6 ± 1.4 years. Time of progression to severe stage of Alzheimer's disease was slower in patients under treatment with vitamin D compared with those without treatment (5.4 ± 0.4 years vs. 4.4 ± 0.16 years respectively, p=0.003). Treatment with vitamin D may be an independent protecting factor in the progression of Alzheimer's disease.


Assuntos
Doença de Alzheimer/tratamento farmacológico , Vitamina D/uso terapêutico , Vitaminas/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Progressão da Doença , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Índice de Gravidade de Doença
5.
Vertex rev. argent. psiquiatr ; Vertex Rev. Argent. Psiquiatr. (En línea);25(114): 85-91, 2014 Mar-Apr.
Artigo em Espanhol | BINACIS | ID: bin-133355

RESUMO

The aim of the study was to analyze the impact of treatment with vitamin D in the progression of Alzheimers disease. We performed a retrospective study including patients with mild stage of Alzheimers disease with more than four years of follow-up. The presence of cardiovascular risk factors, osteoporosis, treatment with memantine, acetylcholinesterase inhibitors drugs and vitamin D were analyzed as independent variables. Time of progression to moderate and severe Alzheimers disease was analyzed as dependent variable. The analysis was done using multivariate linear regression model, Kaplan Meier analysis, Chi-square and T test. Two hundred and two patients met the inclusion criteria. 11


of the patients (n = 23) remained in the mild stage of the disease, 54


(n = 110) developed the moderate form in a mean time of 3 ± 1.4 years while 35


(n = 69) developed the severe form in a mean time of 4.6 ± 1.4 years. Time of progression to severe stage of Alzheimers disease was slower in patients under treatment with vitamin D compared with those without treatment (5.4 ± 0.4 years vs. 4.4 ± 0.16 years respectively, p=0.003). Treatment with vitamin D may be an independent protecting factor in the progression of Alzheimers disease.


Assuntos
Doença de Alzheimer/tratamento farmacológico , Vitamina D/uso terapêutico , Vitaminas/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Progressão da Doença , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Índice de Gravidade de Doença
6.
Vertex rev. argent. psiquiatr ; Vertex Rev. Argent. Psiquiatr. (En línea);25(114): 85-91, 2014 Mar-Apr.
Artigo em Espanhol | LILACS, BINACIS | ID: biblio-1176962

RESUMO

The aim of the study was to analyze the impact of treatment with vitamin D in the progression of Alzheimer’s disease. We performed a retrospective study including patients with mild stage of Alzheimer’s disease with more than four years of follow-up. The presence of cardiovascular risk factors, osteoporosis, treatment with memantine, acetylcholinesterase inhibitors drugs and vitamin D were analyzed as independent variables. Time of progression to moderate and severe Alzheimer’s disease was analyzed as dependent variable. The analysis was done using multivariate linear regression model, Kaplan Meier analysis, Chi-square and T test. Two hundred and two patients met the inclusion criteria. 11


of the patients (n = 23) remained in the mild stage of the disease, 54


(n = 110) developed the moderate form in a mean time of 3 ± 1.4 years while 35


(n = 69) developed the severe form in a mean time of 4.6 ± 1.4 years. Time of progression to severe stage of Alzheimer’s disease was slower in patients under treatment with vitamin D compared with those without treatment (5.4 ± 0.4 years vs. 4.4 ± 0.16 years respectively, p=0.003). Treatment with vitamin D may be an independent protecting factor in the progression of Alzheimer’s disease.


Assuntos
Doença de Alzheimer/tratamento farmacológico , Vitamina D/uso terapêutico , Vitaminas/uso terapêutico , Estudos Retrospectivos , Feminino , Humanos , Idoso , Masculino , Pessoa de Meia-Idade , Progressão da Doença , Índice de Gravidade de Doença
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA